Comparison of metabolic effects of the progestational androgens dimethandrolone undecanoate and 11β‐MNTDC in healthy men
Autor: | Rachelle Bross, Jill Long, Ronald S. Swerdloff, Laura Hull, Arthi Thirumalai, Diana L. Blithe, Peter Liu, Frances A Fernando, Stephanie T. Page, Christina Wang, Youngju Pak, Fiona Yuen |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
Blood Glucose Male medicine.medical_specialty Urology Endocrinology Diabetes and Metabolism medicine.medical_treatment Administration Oral Weight Gain Placebo Article Young Adult 03 medical and health sciences 0302 clinical medicine Endocrinology Sex hormone-binding globulin Insulin resistance Oral administration Sex Hormone-Binding Globulin Internal medicine Humans Insulin Nandrolone Medicine 030219 obstetrics & reproductive medicine biology Adiponectin business.industry Cholesterol HDL Contraceptive Agents Male Dimethandrolone Cholesterol LDL Fasting medicine.disease Healthy Volunteers Hematocrit Reproductive Medicine Dimethandrolone-undecanoate Androgens biology.protein Insulin Resistance business |
Zdroj: | Andrology |
ISSN: | 2047-2927 2047-2919 |
DOI: | 10.1111/andr.13025 |
Popis: | Background Dimethandrolone (DMA) and 11β-methyl-19-nortestosterone (11β-MNT) are two novel compounds with both androgenic and progestational activity that are under investigation as potential male hormonal contraceptives. Their metabolic effects have never been compared in men. Objective Assess for changes in insulin sensitivity and adiponectin and compare the metabolic effects of these two novel androgens. Materials/methods In two clinical trials of DMA undecanoate (DMAU) and 11β-MNT dodecylcarbonate (11β-MNTDC), oral prodrugs of DMA and 11β-MNT, healthy men received drug, or placebo for 28 days. Insulin and adiponectin assays were performed on stored samples. Mixed model analyses were performed to compare the effects of the two drugs. Student's t test, or the non-parametric Kruskal-Wallis test as appropriate, was used to evaluate for an effect of active drug versus placebo. Results Class effects were seen, with decrease in HDL-C and SHBG, and increase in weight and hematocrit, with no statistically significant differences between the two compounds. No changes in fasting glucose, fasting insulin, or HOMA-IR were seen with either compound. There was a slight decrease in adiponectin with DMAU that was not seen with 11β-MNTDC. An increase in LDL-C was seen with 11β-MNTDC but not with DMAU. Discussion There were no significant changes in insulin resistance after 28 days of oral administration of these novel androgens despite a mild increase in weight. There may be subtle differences in their metabolic impacts that should be explored in future studies. Conclusion Changes in metabolic parameters should be carefully monitored when investigating androgenic compounds. |
Databáze: | OpenAIRE |
Externí odkaz: | |
Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |